Following the January meetings of GMMMG and CEGC, the following actions have been published to the GMMMG website.

Updates to guidelines include:

Formulary and RAG updates include:

  • Tocilizumab added as RED for COVID-19. Casirivimab / imdevimab (Ronapreve) for COVID-19 removed from formulary. Other medicines for COVID-19 updated to link to current guidance.
  • DNP entry for prednisolone enteric coated tablets amended to include only the 1mg tablets
  • Mavacamten added to the RAG list as RED

Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the formulary change log available on the formulary page.

The following decisions await approval by the GM ICB Executive:

  • Micronised progesterone (Gepretix) to be added to formulary for HRT
  • Temporary suspension of certain conditions from GM commissioning statement on conditions for which over the counter items should not routinely be prescribed, and permanent amendments to the policy to reflect the national Pharmacy First scheme.